NOVO-B:CPH
Novo Nordisk A/S
260,90 DKK
arrow_downward
-0,97%(-2,55) 1D
16 okt, 15:25:28 GMT+2 · DKK
search
Bütün simvollar
| Simvol | Qiymət | Dəyişiklik | % Dəyişiklik |
|---|
insights_autoNOVO-B üçün ən vacib statistik məlumatlar yaradılır...
Açın
261,00 DKK
Yüksək
262,15 DKK
Aşağı
259,35 DKK
Bazar kapitalizasiyası
870,08 mlrd
Ortalama həcm
5,23 mln
Həcm
1,32 mln
52 həftəlik ən yüksək
409,95 DKK
52 həftəlik ən aşağı
224,25 DKK
Dövriyyədəki səhmlər
3,39 mlrd
İşçilərin sayı
67K
Açın
261,00 DKK
Yüksək
262,15 DKK
Aşağı
259,35 DKK
Bazar kapitalizasiyası
870,08 mlrd
Ortalama həcm
5,23 mln
Həcm
1,32 mln
52 həftəlik ən yüksək
409,95 DKK
52 həftəlik ən aşağı
224,25 DKK
Dövriyyədəki səhmlər
3,39 mlrd
İşçilərin sayı
67K
Xəbər materialları
Veb mənbələri və xəbər partnyorlarından
ad-hoc-news.de
·
4 saat öncə
UBS keeps DKK 332 target for Novo Nordisk stock
ad-hoc-news.de
·
7 saat öncə
Novo Nordisk stock pre-market at EUR 35.04
Foreign Policy Journal
·
11 saat öncə
Novo Nordisk (NYSE: NVO) Stock Price May Be 63% Undervalued As Buyback And Pipeline Catalysts Mount
TradingKey
·
19 saat öncə
Novo Nordisk A/S Stock (NVO) Moved Up by 3.38% on Oct 15: What Investors Need To Know
Profil
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily diabetes and obesity medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 68,800 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark, and it became the highest valued company in Europe. Wikipedia
Novo Nordisk A/S haqqında
Baş İcraçı DirektorMaziar Mike Doustdar
İşçilər66,7K
Təsis Tarixi1923
Baş OfisBagsværd, Capital Region of Denmark, Danimarka
SektorPharmaceutical industry
Veb-saytnovonordisk.com